Ramucirumab (IMC-1121B): Monoclonal Antibody Inhibition of Vascular Endothelial Growth Factor Receptor-2

被引：63

作者：

Spratlin, Jennifer ^{[1
]}

机构：

[1] Univ Alberta, Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada

来源：

CURRENT ONCOLOGY REPORTS | 2011年 / 13卷 / 02期

关键词：

Angiogenesis; Vascular endothelial growth factor receptor; Monoclonal antibody; IMC-1121B; Ramucirumab; Targeted therapy; PHASE-I SAFETY; DAYS ON/7 DAYS; RAF KINASE; CANCER; ANGIOGENESIS; VEGF; AFFINITY; TRAP; PHARMACOKINETICS; BAY-43-9006;

D O I：

10.1007/s11912-010-0149-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Angiogenesis, a well-recognized characteristic of malignancy, has been exploited more than any other pathway targeted by biologic anti-neoplastic therapies. Vascular endothelial growth factor receptor-2 (VEGFR-2) is the critical receptor involved in malignant angiogenesis with its activation inducing a number of other cellular modifications resulting in tumor growth and metastases. Ramucirumab (IMC-1121B; ImClone Systems Corporation, Branchburg, NJ) is a fully human monoclonal antibody developed to specifically inhibit VEGFR-2. Ramucirumab is currently being investigated in multiple clinical trials across a variety of tumor types. Herein, angiogenesis inhibition in cancer is reviewed and up-to-date information on the clinical development of ramucirumab is presented.

引用

页码：97 / 102

页数：6

共 40 条

[1] Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours [J].